Article citationsMore>>

Losenga, L.O., Dikati, N.M., Bongenya, B.I., Ntumba, T.K., Booto, G.I., Dembo, R.D., Selenge, S.M., Nonga, J.E., Kabamba, C.A., Sombo, M.-T.A.S., Bumoko, G.M.M. and Kamangu, E.N. (2022) Sociodemographic and Anthropometric Profile of People Living with Human Immunodeficiency Virus Starting Treatment in Kinshasa, Democratic Republic of the Congo. Open Access Library Journal, 9, e9056.
https://doi.org/10.4236/oalib.1109056

has been cited by the following article:

• TITLE: Virological and Molecular Profile of People Living with HIV after 24 Weeks of Treatment with Dolutegravir in Kinshasa

  AUTHORS: Berry I. Bongenya, Charlotte Tshinguta, Benoit O. Kabengele, Marie-Thérèse A. S. Sombo, Guy M. M. Bumoko, Mariano M. Lusakibanza, Gauthier K. Mesia, Erick N. Kamangu

  KEYWORDS: Virological Profile, Molecular, PLHIV, 6 Months of ART, Dolutegravir, Kinshasa

  JOURNAL NAME: World Journal of AIDS, Vol.13 No.4, November 10, 2023

  ABSTRACT: Context: The appointment of the M6 is crucial because it is an indicator of the prognosis of the evolution of the care and the decision-making on the continuation of the AntiRetroViral Treatment. Objective: The objective of this study is therefore to present the virological and molecular profile of People Living with HIV under treatment with Dolutegravir 6 months after being put on ART in Kinshasa. Methods: The present study is a cross-sectional view at the sixth month of a prospective cohort to determine the virological and molecular profile of People Living with HIV (PLHIV) after 6 months of ART based on Dolutegravir (DTG) in Kinshasa. A sample of 5 mL of blood was taken from all HIV patients included. The collection of biological data was carried out under the same conditions as at inclusion. After extraction, Quantitative Real-Time PCR was carried out to determine the quantity of HIV RNA in the samples according to the protocols previously described. Reverse Transcription PCR (RT-PCR) and Nested PCR were carried out to amplify the regions of interest for Protease and Reverse Transcriptase for sequencing. Results: The median VL value was 2.92 log10 RNA copies/mL. With 17.75% of patients experiencing major failure of first-line treatment. Subtype A is dominant with 13 cases (20.98%); followed by CRF_02AG (16.13%), subtypes C (14.52%), D (9.68%) and K (6.45%). The K65R (3 cases), T69P/N (6 cases), K70R (9 cases) and M184V (8 cases) mutations were listed as existing mutations for Nucleotide Reverse Transcriptase Inhibitors. Conclusion: After 6 months of ART, 59.67% of People Living with HIV on Tenofovir-Lamivudine-Dolutegravir is in therapeutic success while 40.33% are in a state of treatment failure. Subtype A remains dominant in the population of PLHIV. Resistance mutations were detected for Lamivudine and Tenofovir, but none for Dolutegravir.